S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction
暂无分享,去创建一个
G. D'Haens | R. Panaccione | S. Danese | J. Panés | T. Hisamatsu | P. Bossuyt | Kori L Wallace | W. Duan | A. Song | E. Neimark | X. Liao | K. Kligys | J. Zambrano